Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MMP8 | P22894 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | FCER2 | P06734 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976068 | 1.00 | MEN1 (0.56) | MEN1KMT2AHPGDMMP8ALDH1A1 | |
| SCHEMBL338918 | 0.89 | MMP8 (0.54) | MEN1KMT2AHPGDMMP8ALDH1A1 | |
| SCHEMBL17710657 | 0.86 | MEN1 (0.53) | MEN1KMT2AHPGDMMP8ALDH1A1 | |
| SCHEMBL18426210 | 0.86 | KMT2A (0.58) | MEN1KMT2AHPGDMMP8ALDH1A1 | |
| SCHEMBL5866871 | 0.82 | ALDH1A1 (0.71) | MEN1KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL22247521 | 0.82 | EPHX2 (0.52) | MEN1KMT2AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL17722006 | 0.79 | REN (0.48) | MEN1KMT2AHPGDALDH1A1MAPT | |
| SCHEMBL3872511 | 0.78 | KMT2A (0.55) | MEN1KMT2AHPGDMMP8ALDH1A1 | |
| SCHEMBL2299158 | 0.78 | MEN1 (0.55) | MEN1KMT2AHPGDMMP8ALDH1A1 | |
| SCHEMBL21233937 | 0.78 | MEN1 (0.65) | MEN1KMT2AHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851651-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-12-14 | — | — | US | claimed |
| EP-1841726-B1 | AN ASYMMETRIC SYNTHESIS OF (S)-(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | TEVA PHARMA (IL) | 2012-10-31 | — | — | EP | disclosed |
| US-8212071-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-07-03 | — | — | US | disclosed |
| US-7973196-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-07-05 | — | — | US | disclosed |
| US-7960583-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-06-14 | — | — | US | disclosed |
| US-7923575-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2011-04-12 | — | — | US | disclosed |
| US-20100324307-A1 | NOVEL ASYMMETRIC SYNTHESIS OF (S)-(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | KANSAL VINOD KUMAR | 2010-12-23 | — | — | US | disclosed |
| US-7851651-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-12-14 | — | — | US | disclosed |
| US-20100081841-A1 | Novel asymmetric synthesis of (s)-(+)-3-(AMINOMETHYL)-5- methylhexanoic acid | KANSAL VINOD KUMAR | 2010-04-01 | — | — | US | disclosed |
| US-7687656-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-30 | — | — | US | disclosed |
| US-7586005-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-09-08 | — | — | US | disclosed |
| US-20090069578-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | KANSAL VINOD KUMAR | 2009-03-12 | — | — | US | disclosed |
| US-20090069596-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | KANSAL VINOD KUMAR | 2009-03-12 | — | — | US | disclosed |
| US-20090069600-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | KANSAL VINOD KUMAR | 2009-03-12 | — | — | US | disclosed |
| US-20090069593-A1 | intermediates for synthesis of (S)-Pregabalin; anticonvulsants; crystalline form | KANSAL VINOD KUMAR | 2009-03-12 | — | — | US | disclosed |
| US-20090062562-A1 | Novel asymmetric synthesis of (S)-(+)-3-(Aminomethyl)-5-methylhexanoic acid | KANSAL VINOD KUMAR | 2009-03-05 | — | — | US | disclosed |
| US-7446220-B2 | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-11-04 | — | — | US | disclosed |
| US-20070197827-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197827-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | RIMKLA, COASY, GABRE | MEN1 3041/4885KMT2A 1689/4885HPGD 959/4885 |
| US-20090069593-A1 | intermediates for synthesis of (S)-Pregabalin; anticonvulsants; crystalline form | GABRE, GABRA5, GABRA6 | MEN1 3106/4885KMT2A 2881/4885HPGD 460/4885 |
| US-20090069596-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | RIMKLA, COASY, GABRE | MEN1 3041/4885KMT2A 1689/4885HPGD 959/4885 |
| US-20100081841-A1 | Novel asymmetric synthesis of (s)-(+)-3-(AMINOMETHYL)-5- methylhexanoic acid | RIMKLA, COASY, GABRE | MEN1 3041/4885KMT2A 1689/4885HPGD 959/4885 |
| US-20100324307-A1 | NOVEL ASYMMETRIC SYNTHESIS OF (S)-(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | RIMKLA, COASY, GABRE | MEN1 3041/4885KMT2A 1689/4885HPGD 959/4885 |
| US-20090062562-A1 | Novel asymmetric synthesis of (S)-(+)-3-(Aminomethyl)-5-methylhexanoic acid | RIMKLA, COASY, GABRE | MEN1 3041/4885KMT2A 1689/4885HPGD 959/4885 |
| US-20090069578-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | RIMKLA, COASY, GABRE | MEN1 3041/4885KMT2A 1689/4885HPGD 959/4885 |
| US-20090069600-A1 | Novel asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid | RIMKLA, COASY, GABRE | MEN1 3041/4885KMT2A 1689/4885HPGD 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.